BTK inhibitor

BTK inhibitors

is Bruton's tyrosine kinase (BTK),Key tyrosine kinases involved in B cell receptor (BCR) signalingand plays a crucial role in B-cell activation, proliferation, and survival. BTK inhibitors block this function of BTK toMolecular targeted drugs that suppress B cell proliferation and survival signalsIt is primarily used for B-cell malignancies such as chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia, and has been developed as a treatment that targets signaling pathways involved in cancer cells. BTK inhibitors are now positioned as one of the representative drug discovery classes of molecular targeted therapy.

Representative examples of BTK inhibitors

Imbruvica

Ibrutinib (Imbruvica) isFirst-generation BTK inhibitorsis a representative drug widely known as. To the cysteine residue of BTKIrreversibly inhibit by covalent bondThis suppresses B-cell receptor signaling. A representative example of a BTK inhibitor is used in the treatment of B-cell malignancies.

Acalabrutinib (Calquence)

Acalabrutinib (Calquence) is aSecond-generation BTK inhibitorsIts development as a drug.Designed to reduce side effects by increasing selectivity for BTKThis is characterized by a reduced off-target effect compared to the first-generation ibrutinib.

Zanubrutinib (Brukinsa)

Zanubrutinib (Brukinsa) isSecond-generation BTK inhibitorsIts development as a drug.High BTK occupancy and excellent selectivityfeaturing a design aimed at reducing off-target effects while maintaining target inhibition. As a next-generation BTK inhibitor, it is expected to further improve efficacy and safety.

Key challenges in BTK inhibitor development

Overcoming Resistance Mutations

With BTK inhibitors,Reduced binding due to BTK C481S mutationand ...,Activation of BTK downstream signaling, such as PLCγ2 mutationsResistance is a challenge. Resistance development with long-term administration has also been reported, and the development of next-generation BTK inhibitors is progressing. To overcome resistance, evaluation using resistant cell lines and patient-derived models is important.

Balancing BTK selectivity and off-target effects

BTK inhibitors areActs on kinases other than BTK, such as TEC, EGFR, and ITK.This can lead to off-target effects, which can result in side effects. The development of BTK inhibitors with enhanced target selectivity is progressing, and it is important to appropriately evaluate selectivity for BTK in drug discovery.

How to predict drug efficacy and safety in humans

BTK isExpressed on normal B cells.It is being done, so inhibition can affect immune function. In clinical practice,Bleeding, infections, cardiovascular adverse eventsposing a challenge, and cell lines alone cannot fully predict human efficacy. Therefore, efficacy and safety evaluation using disease models with high human translatability is important.

Non-clinical evaluations required for BTK inhibitor development

Build an evaluation system capable of reproducing resistance mechanisms.

In the development of BTK inhibitors,Resistance models for predicting drug efficacy after resistance acquisitionThis is important. By combining cell lines that have introduced resistance mutations, such as BTK C481S, with patient-derived cells and PDX models, we can evaluate next-generation BTK inhibitors and test resistance-overcoming strategies under conditions that are closer to actual clinical practice.

Multifaceted evaluation of action on targets and selectivity

In the evaluation of BTK inhibitors,Confirmation of target binding by target engagementIn addition, it is important to combine BTK signal inhibition assessment, biomarker assessment, and pharmacodynamic studies. It is also important to evaluate not only on-target effects but also off-target effects.A comprehensive evaluation strategy combining multiple evaluation systemsVerified for efficacy and safety.

Integrate and evaluate pharmacokinetics and pharmacodynamics

In the PK evaluation,To understand blood exposure and tissue distribution and whether the drug adequately reaches the target site.confirm. FurtherCombine PK/PD evaluation with efficacy evaluationTherefore, it is important to distinguish whether the cause of insufficient efficacy is due to pharmacokinetics or the drug's efficacy itself, in order to proceed with development efficiently.

Evaluate safety from the early stages of development

With BTK inhibitors,Evaluate bleeding risk, cardiovascular safety, and immunotoxicity from the early stages of development.It is important. In addition to representative safety evaluations such as the hERG assay, toxicity evaluations considering long-term administration are required, and an evaluation strategy that combines necessary safety tests according to the characteristics of the modality is needed.

Key points when choosing a contract research organization (CRO) for non-clinical studies

In the development of BTK inhibitors, non-clinical studies that comprehensively evaluate resistance mechanisms, target selectivity, efficacy, pharmacokinetics, and safety are crucial. As next-generation drugs and novel modalities are developed in the future, selecting a CRO that can propose and implement evaluation systems tailored to the development strategy will lead to efficient drug discovery success.